BG:VIEBAWAG Group AG Analysis
Data as of 2026-03-13 - not real-time
$124.73
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading well above its short‑term and medium‑term moving averages, with momentum indicators showing a bullish tilt – the RSI sits in the upper range and the MACD line sits above its signal, while volume has been on the rise. These technical signs suggest continued upward pressure but the price is also significantly above the discounted cash‑flow estimate, indicating a valuation gap. Volatility is moderate and beta is low, pointing to relatively stable price swings relative to the market.
Recent earnings releases highlighted a substantial jump in revenue following the Viterra integration, yet margins remain thin and free cash flow is negative, compounded by a high debt load. The dividend payout ratio is moderate but cash generation concerns raise questions about long‑term sustainability. An upcoming investor day could provide clarity on cost‑saving synergies and debt‑reduction plans, which will be pivotal for future price direction.
Recent earnings releases highlighted a substantial jump in revenue following the Viterra integration, yet margins remain thin and free cash flow is negative, compounded by a high debt load. The dividend payout ratio is moderate but cash generation concerns raise questions about long‑term sustainability. An upcoming investor day could provide clarity on cost‑saving synergies and debt‑reduction plans, which will be pivotal for future price direction.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical setup with price above key moving averages
- Significant valuation premium to DCF estimate
- Upcoming investor day could shift sentiment
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Revenue surge driven by Viterra integration
- Earnings beat and strong top‑line momentum
- Potential operational synergies improving cash generation
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- High debt burden limiting financial flexibility
- Dividend sustainability concerns amid negative free cash flow
- Valuation gap suggests limited upside without structural improvements
Key Metrics & Analysis
Financial Health
Revenue Growth75.50%
Profit Margin1.16%
P/E Ratio25.3
ROE5.96%
ROA2.51%
Debt/Equity91.01
P/B Ratio1.5
Op. Cash Flow$844.0M
Free Cash Flow$-7106500096
Technical Analysis
TrendBullish
RSI63.8
Support$111.72
Resistance$127.24
MA 20$120.54
MA 50$113.55
MA 200$92.27
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair Value$42.21
Target Price$131.60
Upside/Downside5.51%
GradeOvervalued
TypeGrowth
Dividend Yield2.23%
Risk Assessment
Beta0.51
Volatility26.90%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.